metformin has been researched along with Prader-Willi Syndrome in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 7.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| " We conducted a pilot, open-label study of response to metformin in 21 children with PWS and six with early morbid obesity (EMO)." | 7.80 | Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. ( Dykens, EM; Linville, TD; Miller, JL, 2014) |
| " Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults." | 3.88 | Metformin as targeted treatment in fragile X syndrome. ( Dy, ABC; Eldeeb, M; Hagerman, R; Salcedo-Arellano, MJ; Tartaglia, N; Tassone, F, 2018) |
| " We conducted a pilot, open-label study of response to metformin in 21 children with PWS and six with early morbid obesity (EMO)." | 3.80 | Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. ( Dykens, EM; Linville, TD; Miller, JL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dy, ABC | 1 |
| Tassone, F | 1 |
| Eldeeb, M | 1 |
| Salcedo-Arellano, MJ | 1 |
| Tartaglia, N | 1 |
| Hagerman, R | 1 |
| Miller, JL | 1 |
| Linville, TD | 1 |
| Dykens, EM | 1 |
| Cyganek, K | 1 |
| Koblik, T | 1 |
| Kozek, E | 1 |
| Wojcik, M | 1 |
| Starzyk, J | 1 |
| Malecki, MT | 1 |
| Chan, NN | 1 |
| Feher, MD | 1 |
| Bridges, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)[NCT03862950] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-05-24 | Recruiting | ||
| [NCT01542242] | Phase 4 | 1 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Subject withdrew) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for metformin and Prader-Willi Syndrome
| Article | Year |
|---|---|
Metformin as targeted treatment in fragile X syndrome.
Topics: Adult; Animals; Child; Child, Preschool; Diabetes Mellitus, Type 2; Female; Fragile X Syndrome; Gluc | 2018 |
Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study.
Topics: Adolescent; Age of Onset; Child; Female; Glucose Tolerance Test; Humans; Hyperphagia; Male; Metformi | 2014 |
Liraglutide therapy in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; H | 2011 |
Metformin therapy for diabetes in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Obesity; Prader | 1998 |